The estimated Net Worth of Eduardo Marban is at least $1.12 Million dollars as of 18 August 2015. Eduardo Marban owns over 18,400 units of Capricor Therapeutics Inc stock worth over $1,122,568 and over the last 9 years Eduardo sold CAPR stock worth over $0.
Eduardo has made over 1 trades of the Capricor Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Eduardo bought 18,400 units of CAPR stock worth $80,224 on 18 August 2015.
The largest trade Eduardo's ever made was buying 18,400 units of Capricor Therapeutics Inc stock on 18 August 2015 worth over $80,224. On average, Eduardo trades about 18,400 units every 0 days since 2015. As of 18 August 2015 Eduardo still owns at least 268,557 units of Capricor Therapeutics Inc stock.
You can see the complete history of Eduardo Marban stock trades at the bottom of the page.
Eduardo's mailing address filed with the SEC is C/O CAPRICOR THERAPEUTICS, INC., 8840 WILSHIRE BLVD., 2ND FLOOR, BEVERLY HILLS, CA, 90211.
Over the last 11 years, insiders at Capricor Therapeutics Inc have traded over $949,404,468 worth of Capricor Therapeutics Inc stock and bought 6,444,826 units worth $18,843,106 . The most active insiders traders include Sinai Medical Center Cedars, John Edward A.Edward St. Jo... und Gregory W Schafer. On average, Capricor Therapeutics Inc executives and independent directors trade stock every 58 days with the average trade being worth of $494,068. The most recent stock trade was executed by David B Musket on 7 August 2024, trading 34,000 units of CAPR stock currently worth $47,260.
capricor therapeutics, inc. (nasdaq: capr) is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. our innovative technology builds upon a large body of scientific research and enables us to approach the treatment of diseases in novel ways. capricor’s lead candidate, cap-1002, is an “off-the-shelf” cardiac cell therapy that is currently in clinical development for the treatment of duchenne muscular dystrophy (dmd). cap-1002 consists of allogeneic cardiosphere-derived cells, or cdcs, a unique population of cells which include progenitor cells that have been shown to exert potent immunomodulatory activity, which alters the immune system’s activity to stimulate cellular regeneration. cdcs have been the subject of over 100 peer-reviewed scientific publications and have been administered to approximately 140 human subjects across several clinical trials. capricor has
Capricor Therapeutics Inc executives and other stock owners filed with the SEC include: